# Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease

> **NCT00760435** · PHASE3 · COMPLETED · sponsor: **University of California, San Diego** · enrollment: 196 (actual)

## Conditions studied

- Kawasaki Disease

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00760435
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2014-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00760435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00760435, "Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00760435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*